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Abstract
rs143383 is a C to T transition SNP located in the 59untranslated region (59UTR) of the growth differentiation factor 5 gene
GDF5. The T allele of the SNP is associated with increased risk of osteoarthritis (OA) in Europeans and in Asians. This
susceptibility is mediated by the T allele producing less GDF5 transcript relative to the C allele, a phenomenon known as
differential allelic expression (DAE). The aim of this study was to identify trans-acting factors that bind to rs143383 and
which regulate this GDF5 DAE. Protein binding to the gene was investigated by two experimental approaches: 1)
competition and supershift electrophoretic mobility shift assays (EMSAs) and 2) an oligonucleotide pull down assay
followed by quantitative mass spectrometry. Binding was then confirmed in vivo by chromatin immunoprecipitation (ChIP),
and the functional effects of candidate proteins investigated by RNA interference (RNAi) and over expression. Using these
approaches the trans-acting factors Sp1, Sp3, P15, and DEAF-1 were identified as interacting with the GDF5 59UTR.
Knockdown and over expression of the factors demonstrated that Sp1, Sp3, and DEAF-1 are repressors of GDF5 expression.
Depletion of DEAF-1 modulated the DAE of GDF5 and this differential allelic effect was confirmed following over expression,
with the rs143383 T allele being repressed to a significantly greater extent than the rs143383 C allele. In combination, Sp1
and DEAF-1 had the greatest repressive activity. In conclusion, we have identified four trans-acting factors that are binding
to GDF5, three of which are modulating GDF5 expression via the OA susceptibility locus rs143383.
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Introduction
Osteoarthritis (OA) is a common disease of the synovial joints,
affecting millions of people worldwide. It is a chronic, highly
disabling disease, characterised by the progressive loss of articular
cartilage, changes in the subchondral bone, and variable levels of
synovial inflammation [1]. Many patients suffer from joint pain
and tenderness, limiting the functioning of the joint and thus
having a significant impact on quality of life. Furthermore,
evidence is now emerging of an increased mortality risk in OA
patients [2].
Non-steroidal anti-inflammatory drugs (NSAIDs) and cyclo-
oxygenase 2 (COX-2) inhibitors are recommended for the
pharmacological management of OA. Although these have proven
to be effective for pain relief and suppression of inflammation,
these treatments are failing to target the underlying cause and
progression of disease. There has been limited success so far in
trials of disease-modifying drugs, with arthroplasty remaining the
basis for curative therapy [3].
There are a number of risk factors for OA, including age,
gender, mechanical injury and obesity. Genetics contribute a
significant risk to developing the disease, with heritability estimates
ranging from 39–79% dependent on the joint site affected [4]. A
number of genes have been found to harbour OA susceptibility
alleles and genome wide association scans have provided
additional loci worthy of investigation [5]. When a susceptibility
allele has been identified it is necessary to investigate the functional
effect of the polymorphism in order to enhance understanding of
its role in disease aetiology. This information can then be used to
assist in diagnosis, prognosis and to alleviate detrimental genetic
effects by modulating or restoring gene function or expression.
To date, the most reproducible association with OA has been to
rs143383, a C/T single nucleotide polymorphism (SNP) located
within the 59untranslated region (59UTR) of the growth differen-
tiation factor 5 gene GDF5 (HUGO Gene Nomenclature
Committee (HGNC) number 4420). The T allele of the SNP
was first associated with increased risk of OA in an Asian
population, with this association subsequently replicated in
Europeans [6–8]. Haplotype analysis combined with an exami-
nation of promoter activity following the sequential deletion of the
GDF5 promoter/59UTR demonstrated that rs143383 is the causal
SNP, with its T allele mediating reduced expression relative to its
C allele [6]. This phenomenon is known as differential allelic
expression (DAE). A subsequent analysis of RNA extracted from
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the joint tissues of OA patients heterozygous for the SNP revealed
that the GDF5 DAE is active during the disease process, with DAE
observed in cartilage, ligament, synovium, fat pad and meniscus
[7,9]. Overall, these studies demonstrated that a reduction in
GDF5 expression mediated by the T allele of rs143383 is a risk
factor for OA.
GDF5 protein has a vital role in the formation and repair of
joints. It acts as an extracellular signalling molecule, activating the
expression of genes involved in the formation of cartilage and bone
[10]. During joint specification, GDF5 is present within the joint
interzone, and has been found to have a pivotal role during
chondrogenesis [11]. It is expressed in both normal and OA
cartilage, and has been proposed to also be important in cartilage
repair following trauma [12–16]. Rare and highly penetrant
mutations of GDF5 underlie several severe musculoskeletal
conditions, including Hunter-Thompson syndrome, Grebe syn-
drome and Brachdactyly Type C [17–20]. These conditions
present with joint dislocations, which are found to mainly occur in
the knees and hips, shortened limb bones, abnormalities in the
development of the phalangeal joints and brachydactyly.
This essential role of GDF5 during joint development and joint
maintenance has been further demonstrated in the mouse
brachypodism mutation, which is a premature termination codon
of Gdf5 that results in an absence of functional protein from the
mutant allele. Homozygous mice have a number of developmental
abnormalities of both bone and soft tissues whereas heterozygous
mice show no overt growth abnormalities but when challenged are
more susceptible to develop an OA-like phenotype [21,22].
We have previously reported on DEAF-1 (HGNC:14677) as a
potential trans-acting factor that binds to rs143383 [9]. The aim of
our latest study was to perform a more detailed analysis of DEAF-
1 and to identify additional factors that bind differentially to the
two alleles of rs143383 and that could account for the GDF5 DAE
that is mediated by this SNP. We used the human liposarcoma cell
line SW872 for our research since 1) the cell line expresses GDF5;
2) it is heterozygous for rs143383; 3) it also demonstrates GDF5
DAE and 4) it is amenable to a variety of in vitro experimental
manipulations. Since SW872 cells exhibit GDF5 DAE it was
assumed that the trans-acting factors that mediate the DAE were
expressed in these cells.
We used two different approaches to identify the novel trans-
acting factors. The first utilised bioinformatics software to predict
protein binding based on the sequence surrounding rs143383,
followed by electrophoretic mobility shift assays (EMSAs) to screen
these potential candidates. The second approach used an
oligonucleotide pull down assay to isolate proteins binding to the
promoter region of GDF5, followed by quantitative mass
spectrometry, enabling both the identification and quantification
of proteins binding to the C and T alleles of rs143383. Chromatin
Immunoprecipitation (ChIP), luciferase assays and RNA interfer-
ence (RNAi) were then used to confirm binding of the newly
identified candidate proteins in vivo and to assess their role in
mediating GDF5 DAE. The EMSA and RNAi results were then
confirmed using a combination of the chondrosarcoma cell line
SW1353, the osteosarcoma cell line MG63 and human articular
chondrocytes. This study has identified four trans-acting factors
that are binding to GDF5, three of which are modulating the
expression of this important growth factor.
Results
SW872 is a suitable cell line to investigate the GDF5 DAE
mediated by rs143383
As we previously described, the human liposarcoma cell line
SW872 is heterozygous at rs143383, expresses GDF5 and
demonstrates DAE [23]. In this cell line there is a DAE imbalance
of 1.5 between the C and T alleles (Figure 1), which is comparable
to the average DAE observed in human joint tissues [9]. In that
study the level of DAE at rs143383 was found to be similar
between all the joint tissues examined, and was confirmed in
several different cell lines using luciferase reporter assays [9]. This
indicates that the imbalance is not due to a tissue or cell type
specific factor, but instead implies that the same trans-acting factors
are regulating the expression of GDF5 via rs143383 in a number of
cell types. We therefore used the SW872 heterozygous cell line as a
Figure 1. Differential allelic expression (DAE) of GDF5 in SW872
cells assessed using rs143383. The C/T allelic ratio for genomic DNA
(gDNA) and complementary DNA (cDNA) are shown. Genomic DNA was
normalised to 1.0 and then used to compare against the C/T allelic ratio
obtained for cDNA. Error bars denote the standard error of the mean
(SEM). * p,0.05, calculated using a Students 2 tailed t-test, n number of
3.
doi:10.1371/journal.pgen.1003557.g001
Author Summary
GDF5 is an important growth factor that plays a vital role
in the development and repair of articulating joints.
rs143383 is a polymorphism within the regulatory region
of the GDF5 gene and has two allelic forms, C and T.
Genetic studies have demonstrated that the T allele is
associated with an increased risk of osteoarthritis in a
range of ethnic populations whilst previous functional
studies revealed that this allele mediates its effect by
producing less GDF5 transcript than the C allele. In this
study, we sought to identify transcription factors that are
binding to rs143383 and that are responsible for mediating
this differential level of expression. Using two different
approaches we have identified four factors and our
functional studies have revealed that three of these factors
repress GDF5 expression and that DEAF-1 modulates the
differential expression of the two rs143383 alleles. The
factors that we have identified could serve as novel
therapeutic targets, with their depletion restoring the
expression levels of GDF5 in patients with the osteoarthri-
tis susceptibility T allele. The relevance of our results
extends beyond osteoarthritis, since the T allele of
rs143383 is also a risk factor for a number of other
musculoskeletal diseases.
Trans-Acting Regulators of the OA SNP rs143383
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model system for the discovery and investigation of these trans-
acting factors.
Initial assessment of trans-acting factor binding to
rs143383 by EMSAs
We investigated protein complex binding using SW872 nuclear
extract and fluorescently labelled C and T allele probes
(Figure 2A). We observed a similar pattern of protein complex
binding to the two probes. We confirmed the specificity of the
assay by adding unlabelled C and T allele competitors, and the
two specific complexes binding revealed a differential affinity for
the two alleles. For both complexes, binding to the C allele probe
was outcompeted with excess unlabelled C and T allele
competitor, and vice versa for the T allele probe. Higher
concentrations of C allele unlabelled competitor were required
to outcompete binding to the T allele probe and complex binding
was competed from the C allele probe at a lower concentration of
T allele competitor compared to C allele competitor. These results
suggest the two protein complexes bind more avidly to the T allele,
compared to the C allele. We used smaller sized unlabelled
competitors to refine the region of binding of the two complexes;
this assay suggested that the majority of the sequence of the probe
including the rs143383 polymorphic site is required for the
binding of the two complexes (Figure S1). There is a small degree
of competition using the 506 concentration of competitor 1 (215
to +2 relative to rs143383) and competitor 2 (26 to +6) but not
with competitor 3 (23 to +10) suggesting that the region upstream
of the polymorphism may be more important for complex 1 and 2
binding.
Identification of the binding of Sp1 and Sp3
Using the online databases TransFac, Tess and Promo 3.0, we
identified a number of transcription factors that were predicted to
bind to GDF5 within the region containing rs143383. We refined
the number of potential factors using competitors containing the
consensus binding sequence of each factor (competitor sequences
are listed in Table S1). If binding of either complex to the GDF5
probes was competed, the factors were investigated further by the
addition of an antibody targeting the protein to the EMSA binding
reaction. On the addition of a shared Sp1/Sp3/ETF consensus
competitor, binding of both complexes to the GDF5 probes was
competed (Figure 2B). Sp1 (HGNC:11205) and Sp3
(HGNC:11208) had been identified by all three databases. The
addition of an antibody targeting Sp1 resulted in a supershift of the
upper complex and addition of an antibody targeting Sp3
supershifted both the lower, and one of the upper complexes
(Figure 2C). The Sp1 and Sp3 antibodies were the only ones tested
that resulted in supershifts; Figure S2 shows examples of trans-
acting factors that did not supershift, along with a supershifted
Sp1. These results confirm the binding of Sp1 and Sp3 to GDF5 in
vitro in SW872 cells. We subsequently confirmed the binding of
Sp1 and Sp3 using nuclear extracts from the chondrosarcoma cell
line SW1353, the osteosarcoma cell line MG63 and from primary
human articular chondrocytes (HACs; Figure S3A and S3B).
Identification of the binding of P15
We performed an oligonucleotide pull down assay using C and
T allele DNA probes and then identified and quantified the
binding of proteins to each allele using tandem mass tag (TMT) 6-
plex isobaric labelling followed by mass spectrometry. The binding
of activated RNA polymerase II transcriptional coactivator p15
(P15; also known as SUB1 and PC4; HGNC:19985) was identified
in both the C and T allele DNA samples. However, P15 was
reproducibly found to be more abundant in the T allele sample, in
comparison with the C allele sample with an average C/T ratio of
0.67. This protein was absent in the background control sample.
P15 does not have a known binding consensus sequence and we
were therefore not able to use an EMSA to investigate competition
for binding to the fluorescently labelled C and T allele probes.
However, on the addition of an antibody targeting P15, we
observed a decrease in the two specific protein complexes binding
to the two probes (Figure 2D). This was also observed in SW1353
and MG63 cells and in HACs (Figure S3C).
Demonstration of the binding of DEAF-1
Following our previous report that the DEAF-1 consensus
competitor sequence was able to compete binding of proteins to C
and T allele probes [9], we investigated the effect of adding an
antibody targeted against DEAF-1 to our EMSA reaction. We
observed a supershifted complex in both C and T allele probe
reactions, with the complex appearing to be more intense in the T
allele probe sample (Figure 2E). The supershifted complex was also
confirmed using nuclear extract from HACs, with the protein
complexes binding to the C and T allele probes being less intense
than those observed in the SW872 cells (Figure S3D).
P15 was discovered by the oligonucleotide pull down exper-
iment but this technique did not detect Sp1, Sp3 or DEAF-1,
which were instead detected by the EMSA analysis. A possible
explanation for this is the different binding conditions used,
including different salt concentrations, in the pull down assay
versus EMSA. To assess this, we repeated the EMSA using salt
concentrations equivalent to those used in the pull down and
observed that Sp1 and Sp3 were no longer able to bind to the C
and T allele probes (Figure S4). We suspect therefore that this
accounts for the different results obtained between pull down and
EMSA. This result justifies our use of two distinct techniques for
identifying trans-acting factors.
Sp1, Sp3, and P15 bind to GDF5 in vivo
Following the identification and confirmation of the binding of
the Sp1, Sp3, P15 and DEAF-1 trans-acting factors to a GDF5
probe in vitro, we next sought to confirm the binding of these
factors to the GDF5 locus in vivo using ChIP followed by PCR. In
the PCR reaction we amplified the GDF5 exon 1 region,
encompassing rs143383, and the intensities of the PCR products
were clearly greater following ChIP with anti-Sp1, anti-Sp3 and
anti-P15 antibodies relative to the IgG negative control antibody
(Figure 2F). This suggests that this region of GDF5 is enriched for
Sp1, Sp3 and P15 binding. We were unable to examine binding of
DEAF-1 in vivo due to the unavailability of a specific ChIP grade
antibody for this protein.
Sp1, Sp3, P15, and DEAF-1 regulate GDF5 transcriptional
activity
After confirming the binding of these four factors to GDF5, we
then sought to assess if each factor regulates the expression of
GDF5. We first confirmed the expression of Sp1, Sp3, P15 and
DEAF-1 in patient tissue samples; all four genes, in addition to
GDF5, were expressed in cartilage (from OA and non-OA
patients), synovium and fat pad (Figure S5). We next analysed
the effect of Sp1, Sp3, P15 and DEAF-1 depletion on GDF5
expression by RNAi in the SW872 cells. The depletion of the
mRNA for each gene was confirmed by real time RT-PCR and of
Sp1, Sp3 and P15 protein by immunoblotting (Figures 3A and 3B).
Due to the low expression levels of DEAF-1 within SW872 cells,
we had difficulty in confirming the knockdown of the endogenous
Trans-Acting Regulators of the OA SNP rs143383
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Figure 2. EMSA and ChIP analysis in SW872 cells. (A) The addition of increasing concentrations of unlabelled C and T allele competitor were
added to the EMSA reaction containing the C and the T allele probes and SW872 nuclear extract, with the arrows indicating the specific complexes
binding to the probes. (B) The addition of increasing concentrations of the Sp1/Sp3/ETF unlabelled consensus competitor to the EMSA reaction
containing the C or T allele probe. The arrows indicate the two complexes that are competed. (C) Supershift experiment demonstrating the effect of
adding antibodies targeting Sp1, Sp3, and Sp1 and Sp3 together (1+3), compared to the IgG rabbit antibody control (Con) to the EMSA reaction
containing the C or T allele probe. The arrows indicate the supershifted complexes. (D) Demonstration of the effect of adding P15 antibody to the
EMSA reaction, compared to the IgG rabbit antibody control (Con). The arrows indicate the affected complexes. (E) Demonstration of the effect of
adding DEAF-1 (D1) antibody to the EMSA reaction, compared to the IgG rabbit antibody control (Con). The arrow indicates a supershifted complex.
(F) ChIP analysis of Sp1, Sp3 and P15. Sheared genomic DNA was immunoprecipitated with Sp1, Sp3, P15, rabbit polyclonal IgG (negative control)
and anti-acetyl histone H3 (positive control) antibodies and then PCR amplified across exon 1 of GDF5. The input represents 10% of the non-
immunoprecipitated sheared genomic DNA.
doi:10.1371/journal.pgen.1003557.g002
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protein. We therefore confirmed that the siRNA is able to deplete
DEAF-1 protein following the over expression of DEAF-1 EGFP
fusion protein (Figure S6).
The overall expression of GDF5 was increased following
depletion of each factor. For Sp1, Sp3 and P15 depletion, these
increases in GDF5 expression were not significant, whilst a
significant fold change (p,0.001) was observed upon DEAF-1
knockdown (Figure 3C). We next used allele specific real time
PCR to assess if any of the four factors differentially affects
expression of the two alleles of rs143383, and as such could
contribute to the DAE mediated by this SNP. Depletion of Sp1
and Sp3 resulted in small and non-significant increases in the C to
T ratio (ratio of 2.1 in the control (NTsiRNA) to 2.7 (Sp1 siRNA)
or 2.4 (Sp3 siRNA)) whilst P15 depletion did not alter the DAE
(Figure 3D). DEAF-1 depletion increased the DAE from a C/T
ratio of 2.1 in the control (NTsiRNA) to 4.7 (DEAF-1 siRNA) and
this was highly significant (p,0.001, Figure 3D).
We confirmed the effect on overall GDF5 expression in SW1353
cells, with knockdown of the four factors increasing GDF5
expression. In line with that observed in SW872 cells, the
increases in GDF5 expression were not significant following Sp1,
Sp3 and P15 depletion but a significant fold change was observed
upon DEAF-1 knockdown in this chondrosarcoma cell line (Figure
S7). Additionally Sp1, Sp3, P15 and DEAF-1 depletion experi-
ments were performed in HACs. The depletion of the mRNA for
each gene was confirmed by real time RT-PCR and of Sp1, Sp3
Figure 3. GDF5 expression following Sp1, Sp3, P15 and DEAF-1 depletion. (A) Expression levels of Sp1, Sp3, P15 and DEAF-1 mRNA are
shown as a percentage of the control non-targeting siRNA (NTsiRNA) treated cells following Sp1, Sp3, P15 and DEAF-1 siRNA knockdown. Error bars
denote the standard error of the mean (SEM). *p,0.05, calculated relative to the NTsiRNA value using a Students 2 tailed t-test. (B) Immunoblots
demonstrating Sp1, Sp3 and P15 protein depletion following siRNA treatment. Protein extracted from cells treated with the NTsiRNA control were
used for basal protein expression whilst b-Actin was used as a loading control. (C) Fold change in GDF5 expression following Sp1, Sp3, P15 and DEAF-1
siRNA knockdown and shown relative to the NTsiRNA control. Error bars denote the SEM. ***p,0.001, calculated using a ANOVA. (D) The rs143383 C/
T allelic ratio is shown following Sp1, Sp3, P15 and DEAF-1 siRNA knockdown and compared against treatment with the NTsiRNA control. Allelic ratios
were normalised to genomic DNA (gDNA). Error bars denote the SEM. ***p,0.001, calculated using a ANOVA. Each siRNA experiment was performed
3 times each with an n of 3.
doi:10.1371/journal.pgen.1003557.g003
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and P15 protein by immunoblotting (Figure S8; as for SW872,
endogenous DEAF-1 was not detectable in HACs). Depletion of
P15 and DEAF-1 resulted in small and non-significant increases in
GDF5 expression, whilst Sp3 depletion increased GDF5 expression
significantly (p,0.05).
These data suggest that all four factors are involved in the
transcriptional activity of GDF5, each repressing GDF5 expression,
with DEAF-1 having significant repressive effects and also clearly
contributing to GDF5 DAE in the SW872 cells.
Over expression of Sp1, Sp3, and DEAF-1 represses the C
and T alleles
We next over expressed each of the four factors in combination
with a reporter vector that contained the GDF5 promoter and the
59UTR sequence encompassing rs143383 and which drove
expression of the luciferase gene. We used two constructs, one
containing the T allele and the other the C allele of the SNP.
These experiments were performed in the chondrosarcoma cell
line SW1353. We first assessed what effect this single nucleotide
difference mediated on luciferase activity and observed that the
presence of a T allele at rs143383 significantly reduced the
luciferase activity, with an average C/T allelic ratio of 1.2
(p,0.001, Figure 4A), confirming previous findings [9]. Over
expression of Sp1, Sp3, P15 and DEAF-1 fusion proteins was then
confirmed by immunoblotting and immunofluorescence (Figure 4B
and Figure S9 respectively). Over expression of Sp1 decreased the
promoter activity of both C and T allele constructs, with a
significant repressive effect on the T allele (p,0.05; Figure 4A),
significantly increasing the C/T ratio to 1.38 (p,0.01). Over
expression of Sp3 decreased the promoter activity of both the C
and T allele constructs, and this effect was significant with the T
allele construct (p,0.001; Figure 4A) significantly increasing the
allelic ratio to 1.48 (p,0.001). P15 over expression decreased the
promoter activity of both alleles, however, this repressive effect was
not significant (Figure 4A). Finally, DEAF-1 over expression
significantly repressed the promoter activity of both alleles (C and
T alleles p,0.001; Figure 4A), but most notably repressed the T
allele construct, decreasing its activity to near that of the empty
control and significantly increasing the allelic ratio to 1.37
(p,0.01). These results confirm that Sp1, Sp3 and DEAF-1 are
significantly repressing GDF5 expression, and this repression is
greater for the T allele of rs143383. Conversely, P15 only appears
to be mediating a minor, non-significant repressive effect.
Over expression of Sp1, Sp3, and DEAF-1 in different
combinations leads to stronger repressive effects
We next assessed whether the repressive effects seen in the
above experiment would be stronger if the factors were co-
transfected and over expressed together. When Sp1 and Sp3 were
jointly over expressed there was a significantly greater reduction in
expression of both the C and the T alleles relative to when they
were over expressed alone (Figure 5A). Furthermore, the C/T
allelic ratios significantly increased from 1.38 for the Sp1 over
expression and 1.48 for the Sp3 over expression to 1.70 for the
joint over expression (p,0.001 for the joint over expression versus
Sp1 alone and p,0.05 for the joint over expression versus Sp3
alone; Table S2). When Sp1 and DEAF-1 were jointly over
expressed there was a reduction in expression of both the C and T
alleles relative to when they were over expressed alone (Figure 5B).
The C/T allelic ratios increased significantly from 1.38 for Sp1
and 1.37 for DEAF-1 to 1.55 for the joint over expression
(p,0.001 versus C/T). However, these C/T allelic ratio changes
were not significant when compared with Sp1 or DEAF-1 over
expression alone (p= 0.1). Finally, when Sp3 and DEAF-1 were
jointly over expressed, the C/T allelic ratios increased from 1.48
for Sp3 and 1.37 for DEAF-1 to 1.6 for the joint over expression,
and this was a significant C/T difference compared to DEAF-1
over expression alone (p = 0.01). Over expression of P15 in
combination with Sp1, Sp3 or DEAF-1 did not contribute any
further significant repressive effects compared to over expression
of the factors alone (data not shown).
Finally, we performed co-immunoprecipitation experiments
using nuclear extracts from SW1353 cells to show that Sp1, Sp3,
P15 and DEAF-1 directly interact. We observed co-immunopre-
cipitation of Sp1 when Sp3 and DEAF-1-EGFP were immuno-
precipitated (Figure S10A). In the reciprocal experiment, Sp3 and
DEAF-1 were co-immunoprecipitated upon Sp1 immunoprecip-
itation (Figure S10B and S10D). P15 was co-immunoprecipitated
following Sp1, Sp3 and DEAF-1 EGFP immunoprecipitation
(Figure S10C). Finally, Sp3 was co-immunoprecipitated following
DEAF-1 EGFP immunoprecipitation (Figure S10B), and the
reciprocal experiment revealed DEAF-1 co-immunoprecipitation
with Sp3 immunoprecipitation (Figure S10D).
Discussion
The rs143383 T allele has been reproducibly associated with
increased risk of OA, and produces a lower level of expression of
GDF5 relative to the C allele. This DAE is apparent in all tissues of
the articulating joint and also within the rs143383 heterozygote
cell line SW872, which therefore provided us with an ideal model
system to investigate the trans-acting factors mediating this DAE
[9,23].
Using a variety of techniques we identified Sp1, Sp3, P15 and
DEAF-1 as proteins that bind to the two alleles of rs143383.
Depletion of all four increased the expression of GDF5, whilst
DEAF-1 depletion significantly modulated the DAE. Conversely,
the over expression of Sp1, Sp3 and DEAF-1 repressed C and T
allele expression, repressing the T allele more strongly. When over
expressed together, DEAF-1 and Sp1 mediated the greatest overall
repressive effect whereas over expression of Sp1 and Sp3 together
mediated the greatest differential allelic effect, repressing the T
allele to a greater extent than the C allele. Using co-immunopre-
cipitation we demonstrated that these four factors directly interact
with each other.
Overall therefore we have identified trans-acting factors that
bind differentially to the alleles of rs143383 and which contribute
to the DAE that is mediated by this important OA susceptibility
locus.
Sp1 and Sp3 are well characterized transcription factors that
have a high degree of conservation between their zinc finger DNA
binding domains (95% homology) and which bind to related DNA
sequences [24,25]. Sp1 is usually considered a potent activator of
gene expression, although repressive activity has been reported,
whereas Sp3 is known to possess both activator and repressor
functions [26–28]. Both proteins are ubiquitously expressed and
bind with high affinity to GC rich motifs, which are promoter
elements present in a diverse range of genes. The proteins also
form a multi-protein complex to synergistically regulate gene
expression [29]. Promoters that do not contain a TATA binding
site are commonly known to have an Sp protein-binding site. In
these TATA-less promoters Sp1 has been reported to play a
critical role in anchoring the basal transcription machinery to
promote transcriptional initiation. Sp1 facilitates the binding of
TFIID through binding to TBP (TATA binding protein)
associated factors (TAFs) which then recruit RNA polymerase II
[30]. GDF5 does not contain a TATA box and thus it appears
Trans-Acting Regulators of the OA SNP rs143383
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likely that in binding to the GDF5 59UTR, Sp1 and Sp3 may be
mediating interactions with the basal transcriptional machinery to
modulate transcription of this gene.
In our EMSA experiments, a comparison of the complex
formation of Sp1 and DEAF-1 to the GDF5 probes revealed that
there is an abundance of Sp1 protein relative to DEAF-1 protein.
DEAF-1 however has the most significant repressive effect on
GDF5 expression. Sp1 is known to form homomultimers when it is
bound to the promoters of genes, where it can serve as a docking
site for the binding of other proteins [31]. This Sp1 multi-
merisation may account for the relative abundance of this protein.
Sp1 and Sp3 have been previously reported to interact with
HDAC1 in order to mediate gene repression [32]. Our analysis
did not however provide evidence of HDAC1 binding to rs143383
or to its immediate flanking sequence. The importance of Sp1 and
Sp3 during joint development is highlighted by the large number
of target genes that they regulate, the expression of which are key
for the formation of the joint and include SOX9, COL1A1 and
RUNX2 [33–36].
P15 is a small, highly abundant nuclear protein with multiple
functions in transcription, replication and DNA repair [37]. As a
transcriptional co-activator, P15 mediates functional interactions
between transcription factors and the general transcription
machinery [38]. P15 has also been reported to stabilize multi-
protein complexes and has previously been reported to act as a co-
activator of Sp1, where it was reported to function as a linker
between Sp1 and the pre-initiation complex (PIC) [39,40].
Repressor functions of P15 have also been reported [41]. P15
knockout mice are lethal, highlighting the important role of this
factor during development; however heterozygous knockout mice
display no overt phenotype indicating there may be a threshold
level of P15 that is required for normal development.
Sp1, Sp3 and DEAF-1 were not identified by the oligonucle-
otide pull down experiment. We hypothesised that this may be due
to the different salt conditions used between pull down and EMSA
and we then demonstrated that this was the case. This highlights
the importance of using more than one method for the discovery
of trans-acting factors. Another difference between our pull down
Figure 4. Over expression of the Sp1, Sp3, P15, and DEAF-1 proteins. (A) Promoter activity of the C and T GDF5 luciferase vectors is shown
relative to Renilla. Values are normalised to the luciferase levels of the EGFP/pGL3 empty vector (EMPTY). Promoter luciferase levels of both C and T
allele vectors are shown in addition to the empty EGFP vector (C and T) and following over expression of Sp1 (C+Sp1 and T+Sp1), Sp3 (C+Sp3 and
T+Sp3), P15 (C+P15 and T+P15) and DEAF-1 (C+D1 and T+D1). Error bars denote the standard error of the mean (SEM). *p,0.05 **p,0.01 ***p,0.001
n/s = not significant, calculated using a Students 2 tailed t-test. Six replicate experiments were performed, each with an n of 4. (B) Immunoblots
showing Sp1 (Sp1-EGFP), Sp3 (Sp3-EGFP), P15 (P15-EGFP) and DEAF-1 (DEAF1-EGFP) protein levels following over expression compared to the EGFP/
pGL3 combination empty vector control (EGFP). Cells are untreated protein samples whilst b-Actin was used as a loading control. The arrows indicate
basal protein and over expressed protein levels.
doi:10.1371/journal.pgen.1003557.g004
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and EMSA experiments was the length of the genomic DNA
sequence used, which was 212 bp in the pull down and 33 bp in
the EMSAs. We chose to use a long sequence in the pull down in
order not to limit the capture of proteins that may bind over large
DNA regions. It is possible however that by using such a long
sequence we captured non-specific proteins that may have
disrupted the binding of Sp1, Sp3 and DEAF-1. The use of a
shorter DNA sequence or of repeat concatamers of rs143383 and
its immediate flanking sequence, combined with varying salt
concentrations, may have led to the identification of Sp1, Sp3 and
DEAF-1 by the oligonucleotide pull down approach.
Of all of the four trans-acting factors that we identified, DEAF-1
appears to repress GDF5 expression most significantly. The lack of
a ChIP grade antibody precluded us from demonstrating the
binding of DEAF-1 in vivo. However, the EMSA supershift that we
observed combined with the significant changes in both overall
and allelic GDF5 expression following DEAF-1 depletion, and the
significant repressive effects observed following DEAF-1 over
expression, provided us with compelling evidence that this trans-
acting factor is modulating GDF5 expression at rs143383. DEAF-1
is repressing the T allele more avidly, compared with the C allele,
thus following DEAF-1 depletion we expected to observe a greater
increase in the expression of the T allele, and a decrease in the C/
T allelic ratio. Conversely, we observed an increase in the C/T
allelic ratio. We believe this may be either a result of the
incomplete depletion of DEAF-1 protein, or because the other
factors forming part of the repressive complex are continuing to
differentially repress GDF5 expression.
DEAF-1 is expressed in many neuroendocrine and reproductive
tissues and is expressed at high levels in the foetus, suggesting an
important role during development [42]. DEAF-1 regulates the
expression of a number of genes and its transcriptional activity can
Figure 5. Over expression combinations. Promoter activity of the C and T GDF5 luciferase vectors is shown relative to Renilla. Values are
normalised to the luciferase levels of the EGFP/pGL3 empty vector (EMPTY). (A) Promoter luciferase levels of both C and T allele vectors are shown in
addition to the empty EGFP vector (C and T) and following over expression of Sp1 alone (C+Sp1 and T+Sp1), Sp3 alone (C+Sp3 and T+Sp3) and Sp1
and Sp3 in combination (C+Sp1+Sp3 and T+Sp1+Sp3). (B) Promoter luciferase levels of both C and T allele vectors are shown in addition to the empty
EGFP vector (C and T) and following over expression of DEAF-1 alone (C+D1 and T+D1), and DEAF-1 in combination with Sp1 (C+D1+Sp1 and
T+D1+Sp1) and in combination with Sp3 (C+D1+Sp3 and T+D1+Sp3). Error bars denote the standard error of the mean (SEM). *p,0.05 ***p,0.001 n/
s = not significant, calculated using a Students 2 tailed t-test. 3 replicate experiments were performed, each with an n of 4.
doi:10.1371/journal.pgen.1003557.g005
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be modulated by a single base-pair change to its binding site, with
its repressive regulation of the expression of the serotonin auto-
receptor 1A (5HT1A) gene reduced following a C to G
transversion [43,44]. This study confirms our observation that
the activity of DEAF-1 is sensitive to subtle changes in its binding
sequence. DEAF-1 knockout mice display skeletal abnormalities
including rib cage defects, with a large proportion of the animals
suffering from defective neural tube closure that causes death
shortly after birth [45].
Using our experimental data and the predicted binding regions
for each protein we have prepared a model for how we believe
Sp1, Sp3, P15 and DEAF-1 are interacting relative to rs143383
(Figure 6). The core consensus site for DEAF-1 is TCGG, which
resides directly over the SNP, whereas the Sp1/Sp3 GC binding
motif is immediately upstream. Although we have confirmed the
binding of P15 to GDF5 both in vitro and in vivo, P15 is not
mediating a significant repressive effect on GDF5 expression. We
propose therefore that DEAF-1, Sp1 and Sp3 are forming a
repressive complex that forms directly over rs143383 and are
differentially modulating the expression of the C and T alleles. P15
may be interacting with this complex and serving as a linker
between Sp1 and the general transcription machinery. We have
very recently identified YY1 as a transcriptional activator that
binds 80 bp upstream of rs143383, within the GDF5 promoter
[46]; YY1 and Sp1 have previously been shown to jointly
modulate the expression of genes and so it is possible that YY1
may indirectly interact with the complex at rs143383 [47].
The relevance of our results extend beyond OA, since the T
allele of rs143383 has been associated with a number of other
musculoskeletal phenotypes including congenital hip dysplasia
[48], Achilles tendinopathy [49], lumbar disc degeneration [50],
variation in normal height, hip axis length, and an increased risk of
fracture [51,52]. Transcription factors are now becoming more
widely considered as targets for therapeutics to modulate the
expression of genes. One approach that has proven effective in vivo
and which is being considered for clinical application is the
inhibition of transcription factors with molecules that mimic the
transcription factor binding site [53]. This is known as transcrip-
tion factor decoy and Sp1 has already been targeted using this
approach in breast cancer [54]. The factors that we have identified
could therefore serve as novel therapeutic targets, with their
depletion restoring the expression levels of GDF5 in patients with
the OA susceptibility T allele.
Materials and Methods
Cell culture
SW872 cells were cultured in Dulbecco’s modified eagles
medium: Hams F12 nutrient mix, GlutaMAX in a 3:1 ratio
(Invitrogen, Life Technologies, Paisley, UK) containing 5% (v/v)
foetal bovine serum (FBS), 100 U/ml penicillin and 100 mg/ml
streptomycin (Sigma-Aldrich, St. Louis, USA). SW1353 cells were
cultured in Dulbecco’s modified eagles medium: F12 (1:1)
(Invitrogen) containing 10% (FBS), 100 U/ml penicillin,
100 mg/ml streptomycin and 2 mM L-glutamine (Sigma-Aldrich).
Monolayer cultures were maintained in vented T75 cm2 flasks at
37uC, in a 5% CO2 (v/v) atmosphere. MG63 cells were cultured
in Dulbecco’s modified eagles medium (Invitrogen, Life Technol-
ogies) containing 10% (v/v) foetal bovine serum (FBS), 100 U/ml
penicillin, 100 mg/ml streptomycin (Sigma-Aldrich) and 2 mM of
L-glutamine (Sigma-Aldrich). Human articular chondrocytes
(HACs) were isolated from articular cartilage obtained from
patients with osteoarthritis undergoing total hip or knee replace-
ment surgery. HACs were also obtained from non-OA patients
who had undergone joint replacement due to neck-of-femur
(NOF) fracture. Ethical approval and informed consent were
obtained prior to surgery (research ethics committee reference 09/
H0906/72 issued by the UK National Research Ethics Service).
Enzymatic digestion and HAC culture was performed as
previously described [55].
Nucleic acid and protein extraction
Genomic DNA, total RNA and total protein were simulta-
neously extracted from SW872 cells using a spin column
extraction kit according to the manufacturer’s instructions
(Nucleospin Triprep, Macherey-Nagel, supplied by Fisher, UK).
Nucleic acids were quantified using a NanoDrop ND-1000
Spectrophotometer (NanoDrop Technologies, Wilmington, USA).
Gene expression
1 mg of total RNA was DNase treated with 2 units of Turbo
DNase (Ambion, Life Technologies) and reverse transcribed using
Moloney Murine Leukemia Virus (M-MLV; Invitrogen) following
manufacturer’s instructions. Gene expression of GDF5, SP1, SP3,
P15 and DEAF-1 was determined by real time RT-PCR and
normalised to the housekeeping gene HPRT1 using the delta ct
method (22(ct test gene)-(ct HPRT1)). Gene expression assays were
Figure 6. Proposed binding model of the four trans-acting factors to rs143383. A region (+9 to +301 relative to the transcription start site)
of the GDF5 59UTR is depicted, with the sequence immediately flanking rs143383 (T allele underlined) shown. We propose that DEAF-1 binds directly
to rs143383 (at the TTGG site) and that Sp1 and Sp3 bind just upstream (to the Sp site GGGCGG), mediating a repressive effect through DEAF-1. P15
may be interacting with the repressive multi-protein complex and serving as a linker with the general transcription machinery. ORF is the open
reading frame of GDF5 whilst ATG is the translation initiation codon.
doi:10.1371/journal.pgen.1003557.g006
Trans-Acting Regulators of the OA SNP rs143383
PLOS Genetics | www.plosgenetics.org 9 June 2013 | Volume 9 | Issue 6 | e1003557
purchased from either Applied Biosystems (ABI, Life Technolo-
gies) or Integrated DNA Technologies (IDT, Belgium). Differential
Allelic Expression (DAE) analysis, to assess the expression of the C
and T alleles of rs143383, was performed using a custom SNP
genotyping assay (ABI, Life Technologies) containing forward and
reverse primers and allele specific probes (VIC or FAM labelled).
For analysis, the cDNA C/T allelic ratio was normalised to the
genomic DNA (gDNA) C/T allelic ratio (representing a 1:1 ratio)
for each treatment group. An ABI PRISM 7900HT Sequence
detection System was used for all real time PCR quantification. In
SW872 cells for both overall gene expression and DAE analysis,
three independent experiments were performed, with three
biological replicates per experiment (n = 9). For each DNA and
cDNA sample we performed three pipetting replicates, which were
averaged prior to analysis. For SW1353 cells, three independent
experiments were performed (n= 3). For HACs twelve biological
replicates were performed. Statistical analysis of % knockdown
was performed using a Students 2-tailed t-test whilst the one-way
analysis of variance (ANOVA) test was used for GDF5 fold change
and DAE analysis. The primer and probe sequences are listed in
Table S3A.
Nuclear protein extraction
For the extraction of nuclear protein, cells were seeded at a
density of 156106 on 500 cm2 plates (Corning, USA). Two buffers
were used sequentially to isolate nuclear proteins; following
centrifugation (10,000 g 30 seconds) cell pellets were re-suspended
in 1 ml hypotonic buffer (10 mM HEPES pH 7.6, 1.5 mM
MgCl2, 10 mM KCl, 1 mM DTT, 10 mM NaF, 1 mM Na3VO4,
0.1% Tergitol (v/v), 16complete protease inhibitor cocktail tablet
per 50 ml solution (Roche, UK)) and incubated on ice for
15 minutes. After a second centrifugation, the cell pellet was re-
suspended in 500 ml high salt buffer (20 mM HEPES, pH 7.9,
420 mM NaCl, 20% glycerol (v/v), 1 mM DTT, 10 mM NaF,
1 mM Na3VO4, 16complete protease inhibitor cocktail tablet per
50 mls of buffer) and incubated on ice for 30 minutes. Following a
final centrifugation (10,000 g, 2 minutes), the supernatant con-
taining nuclear protein was stored at 280uC.
Bioinformatics search and Electrophoretic Mobility Shift
Assays (EMSA)
PROMO 3.0, TESS, and TransFac online databases were used
to predict protein binding to the C and T-alleles of GDF5.
Fluorescently labelled oligonucleotides for both alleles (Eurofins
MWG Operon, Ebersberg, Germany) were re-suspended to a final
concentration of 100 pmol/ml in water (Sigma-Aldrich). Single-
stranded oligonucleotides were incubated at 95uC for 5 minutes in
a solution containing EMSA annealing buffer (100 mM Tris-HCl
pH 7.5, 500 mM NaCl, 10 mM EDTA) to a final concentration of
20 pmol/ml and cooled slowly to room temperature for 2 hours to
generate double stranded annealed probes. The annealed probes
were diluted to 100 fmol/ml in water (Sigma-Aldrich) prior to the
EMSA reaction. A native 5% (weight/volume) polyacrylamide gel
was prepared the day before the EMSA and allowed to set at 4uC
overnight. The EMSA was then carried out as per manufacturer’s
instructions using the Odyssey Infrared EMSA kit (LiCor
Biosciences, Cambridge, UK). The optimal binding reaction
contained 16 Binding Buffer, 2.5 mM DTT, 1 mg Poly (dI:dC),
5 mM MgCl2, 200 fmol annealed oligonucleotide and 5 mg
nuclear extract. The gel was visualised using an Odyssey Infrared
Imager (LiCor Biosciences). For competition assays to test binding
of predicted proteins, single stranded unlabelled oligonucleotides
(Sigma-Aldrich) containing the consensus binding sequence of the
protein were annealed as previously described for the labelled
probes. For supershift EMSAs, 2 mg of antibody was added to the
binding reaction. Table S1 lists the nucleotide sequences of the
labelled probes and unlabelled competitor sequences. Table S4
provides details of the antibodies.
Oligonucleotide pull down assay and quantitative
tandem mass spectrometry
A 212 bp DNA region encompassing rs143383 was amplified
by PCR using a biotinylated 59 primer and unlabelled 39 primer
(Sigma-Aldrich) (Table S3B). Two PCRs were performed, using
homozygous C or T template DNA at the polymorphic site.
40 pmol of PCR product was coupled to 2 mg of Streptavidin
Dynabeads (Invitrogen) following the manufacturers instructions.
A sample containing no DNA was used as a control. DNA-beads
complexes were blocked as described previously [56]. SW872 cell
nuclear lysates were extracted as described above, transferred to a
tube for dialysis (Tube-O-dialyzer, VWR, UK), and dialyzed in a
low salt buffer (20 mM HEPES pH 7.9, 20% (v/v) glycerol, 0.1 M
KCl, 0.2 mM EDTA, 0.5 mM PMSF, 0.5 mM DTT) for 4 hours
at 4uC. The buffer was replaced and the lysates were dialysed for a
further 16 hours at 4uC. Following this, the nuclear lysate was pre-
cleared for 1 hour with 50 ml Streptavidin Dynabeads (Invitrogen).
DNA-bead complexes were then re-suspended in 1 mg of the
prepared SW872 protein extract and incubated for 2 hours at 4uC
with shaking. Beads were washed six times with BC-100 buffer and
re-suspended in 16 SDS sample buffer (4% SDS, 0.2 M Tris-
HCL, 4% glycerol, 0.01% bromophenol blue, 2% b-mercapto-
ethanol). Complexes were eluted from the beads following
incubation at 95uC for 5 minutes and isolated following magnetic
separation. The samples (CC, TT and no DNA) were loaded on to
a 12% gel, and subject to separation by electrophoresis, followed
by coomassie blue staining. Quantitative mass spectrometry was
performed as previously described [57]. Briefly, following peptide
digestion overnight using trypsin, labelling of the three conditions
was carried out with a TMT isobaric mass tagging kit (Thermo
Scientific, Surrey, UK). Labelled samples were mixed prior to off-
gel fractionation of the peptides. Following liquid chromatography
tandem mass spectrometry (LC-MS/MS), quantitative analysis
was carried out using ProteinExplorer, version 1.0 (Thermo
Scientific) and the search engine MASCOT (Matrix Science
Company) used for identification of proteins. These results were
then sorted according to detection in the background sample and
ranked with the most robust hits being proteins with high
confidence values, based on the identification of more than 2
unique peptide sequences, the coverage of peptides in the protein
and those with low variability between peptide quantification
values. Proteins known to have a role in transcriptional activation
or repression were prioritised for further analysis.
Chromatin Immunoprecipitation (ChIP)
ChIP experiments were performed as recommended by the
manufacturer using the Magna ChIP A kit (Merck, Millipore,
Consett, UK). Briefly, SW872 cells were cultured until 70%
confluent on 500 cm2 culture plates (Corning). Cells were cross
linked for 10 minutes with 1% (w/v) formaldehyde, 1.25 M
glycine was then added for 5 minutes to quench unreacted
formaldehyde. The cells were then washed twice and harvested in
cold PBS containing protease inhibitors. Cells were then
centrifuged for 8 minutes at 720 g, re-suspended in lysis buffer
and incubated on ice for 20 minutes. The cell suspension was
sonicated using a Soniprep150 probe sonicator (MSE UK,
London, UK) to shear the chromatin, and then pre-cleared with
magnetic protein A beads for 30 minutes at 4uC. 100 mg of
chromatin was incubated with rotation overnight at 4uC in
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addition to 10 mg of either rabbit IgG antibody (negative control),
anti-acetyl histone H3 (positive control) or 10 mg of the antibody of
interest and 40 ml magnetic protein A beads (the antibodies used
are listed in Table S4). Using a magnetic separator immunopre-
cipitated DNA/protein complexes were isolated and washed as
recommended. Cross-linking was reversed by incubating the
DNA/protein complexes and the input control (10% of sonicated
chromatin) in elution buffer with proteinase K at 65uC for
2 hours. DNA was purified and analysed by PCR (Table S3B).
2 ml of immunoprecipitated DNA was added to a 15 ml PCR
reaction, the thermocycling conditions as follows; 94uC 14 min-
utes, followed by 32 cycles of 94uC 30 seconds, 57uC for
30 seconds (annealing temperature for GDF5 ChIP primers),
72uC for 30 seconds and a final step of 72uC for 5 minutes. PCR
products were electrophoresed through a 2% (w/v) agarose gel
containing ethidium bromide. Three ChIP experiments in total
were performed for each antibody, each showing consistent results.
RNA-mediated interference
SW872 cells were seeded at 350,000 cells per well in a 6 well
culture plate (Costar, UK). After 24 hours, cells were transfected
using 100 nM Dharmacon ON-TARGETplus Smartpool siRNAs
targeted against SP1, SP3, P15, DEAF-1 and a Non-Targeting Pool
control in addition to Dharmafect 4 lipid reagent (Thermo Fisher,
UK). After 48 hours the cells were harvested, nucleic acid and
protein isolated and RNA reverse transcribed as described above.
Depletion of mRNA expression was calculated compared to cells
transfected with the ON-Targetplus Non-Targeting Pool control
siRNA (Thermo Fisher). SW1353 cells were seeded at 250,000
cells per well in a 6 well culture plate and transfected as described
for SW872 cells using Dharmafect 1 lipid reagent (Thermo Fisher).
Human articular chondrocytes were seeded at 300,000 cells per
well in a 6 well culture plate and transfected as described for
SW872 cells using Dharmafect 1 lipid reagent (Thermo Fisher).
Reporter luciferase assays
The GDF5 promoter and part of the 59UTR region spanning
297 to +305 (relative to the transcriptional start site) was
subcloned from the GDF5 pGL3-Basic vector [46] into the Mlu/
BglII sites of the purified pGL3-Enhancer Vector (Promega, UK).
The Sp1, Sp3 and P15 open reading frames (ORF) were
amplified from cDNA using the primers listed in Table S3B,
ligated into the EcoR1 and SacII sites of the pEGFP-N1 vector
(Clontech) and transformed into MACH1 competent bacterial
cells (Invitrogen). The DEAF-1-EGFP-N1 expression plasmid was
kindly donated by C. Garrison Fathman [58]. Plasmid DNA was
extracted using a Qiagen Maxiprep Kit (Qiagen, Crawley, UK).
SW1353 cells were seeded at a density of 17,500 cells per well in
a 48-well cell culture plate (Costar, UK) and cultured for
48 hours prior to transfection. Cells were transfected with 2 mg of
plasmid DNA (containing 1 mg of GDF5 pGL3 enhancer vector
and several combinations of either 1 mg empty pEGFP-N1
vector, 500 ng empty pEGFP-N1 and one of the transcription
factor expression plasmids, or 500 ng each of two transcription
factor expression plasmids) in addition to 15 ng of pTK-RL
Renilla using ExGen 500 in vitro transfection reagent (Fermentas,
York, UK). Four wells were transfected per condition and a total
of three individual experiments were performed. After 24 hours,
transfected cells were lysed and luciferase and renilla activity
measured using the Dual Luciferase Assay system (Promega, UK)
with the MicroLumat Plus LB96V luminometer (Berthold
Technologies UK, Harpenden, UK). Statistical analysis was
performed using the Students 2-tailed t-test.
Immunoblotting
To assess siRNA knockdown of our candidate proteins and
successful over expression, total protein was isolated as described,
quantified (Bradford reagent, Expedeon) and 10 mg was resolved
on SDS-10% (w/v) polyacrylamide gels. Protein was then
transferred to Immobilon-P PVDF membranes (Merck Millipore).
The antibodies detailed in Table S4 were used to assess protein
levels following siRNA knockdown and over expression in SW872
and SW1353 cells respectively. A monoclonal b-Actin antibody
was used as a loading control. For the examination of protein over
expression, 250,000 cells per well were seeded in 6-well culture
dishes and transfected with plasmid vectors and ExGen500 as
described for the 48-well plate, but the relative amounts of each
were increased according to the culture volume. For the over
expression of DEAF-1 EGFP, followed by DEAF-1 siRNA
treatment, SW872 cells were transfected with DEAF-1 EGFP as
described above, and after 6 hours the cells were treated with
NTsiRNA or with DEAF-1 siRNA and then harvested after
48 hours.
Immunofluorescence
To examine the overexpression of EGFP-N1 vectors, SW1353
cells were seeded at a density of 10,000 cells/well in a chamber
slide (Nagel Nunc International, USA) and after 48 hours,
transfected with 1 mg plasmid vector using ExGen 500. After
24 hours, cells were washed in PBS and fixed with 4% (w/v)
Paraformaldehyde in PBS for 10 minutes, washed again in PBS
and mounted using vectashield with DAPI (496-diamidino-2-
phenylindole) (Vector Laboratories, Burlingame, CA). Fluores-
cence was detected using a LEICA DMLB fluorescent microscope
and a SPOT-RT camera.
Co-immunoprecipitation
SW1353 cells were cultured until 70% confluent on 500 cm2
culture plates (Corning) and nuclear protein was extracted as
described above. 10 mg of antibody and 200 mg of nuclear extract
(diluted 1 in 5 in high salt lysis buffer) was incubated over night at
4uC with shaking. 70 ml magnetic protein A beads were added to
each immunoprecipitation, and this mixture was incubated at 4uC
with shaking for 4 hours. Using a magnetic separator, immuno-
precipitated protein complexes were isolated and washed with lysis
buffer twice and with PBS once. The magnetic beads were then re-
suspended in Laemmli buffer and the samples were heated to
95uC for 5 minutes. The supernatant was then taken forward for
analysis by SDS-PAGE.
Supporting Information
Figure S1 EMSA analysis of the binding region. The addition of
increasing concentrations (106and 506 the probe concentration)
of the unlabelled competitors of varying sizes (full sized
competitor, and three competitors covering different areas: Comp
1, Comp 2 and Comp 3) were added to the EMSA reactions
containing the C or T allele probe. The sequences of each of the
competitors are shown below the EMSAs, with the rs143383
polymorphism highlighted in bold and underlined.
(TIF)
Figure S2 Antibody supershift experiments performed on several
additional trans-acting factors. Antibodies targeting E2F1 (E2F),
EGR (EGR1), HDAC1 (H1), HDAC2 (H2), KLF16 (KLF) and Sp1
(positive control) were added to the EMSA reactions containing the
C or T allele probe. Con, IgG rabbit antibody control.
(TIF)
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Figure S3 EMSA analysis using different nuclear extracts. (A)
Supershift experiment demonstrating the effect of adding anti-
bodies targeting Sp1 and Sp3 to the EMSA reaction containing
the T allele probe, compared to the IgG rabbit antibody control
(Con). Nuclear extracts from SW872, SW1353 and MG63 cell
lines and from human articular chondrocytes (HAC) were used.
The arrows indicate the supershifted complexes. (B) Supershift
experiment demonstrating the effect of adding antibodies targeting
Sp1 and Sp3 to the EMSA reaction containing the C allele probe,
compared to the IgG rabbit antibody control (Con). Nuclear
extracts from SW872, SW1353 and MG63 cell lines and from
human articular chondrocytes (HAC) were used. The arrows
indicate the supershifted complexes. (C) Demonstration of the
effect of adding P15 antibody to the EMSA reaction containing
the C or T allele probe, compared to the IgG rabbit antibody
control (Con). Nuclear extracts from SW872, SW1353 and MG63
cell lines and from human articular chondrocytes (HAC) were
used. (D) Supershift experiment demonstrating the effect of adding
an antibody targeting DEAF-1 to the EMSA reaction containing
the C or T allele probe, compared to the IgG rabbit antibody
control (Con). Nuclear extract from human articular chondrocytes
(HAC) was used. The arrow indicates the supershifted complex.
(TIF)
Figure S4 EMSA analysis using alternative conditions. EMSA
analysis demonstrating the effect of using both standard conditions
and conditions to mimic the oligonucleotide pull down assay. All
conditions contain either the C or the T allele probe and SW872
nuclear extract. Standard represents the normal EMSA condi-
tions. Condition 1 is an EMSA reaction using the low salt
oligonucleotide pull down buffer. Condition 2 represents 50%
volume of the oligonucleotide pull down buffer diluted in water.
Condition 3 represents the oligonucleotide pull down buffer in
addition to 1 mg poly dI:dC. Condition 4 represents the standard
EMSA conditions in addition to 50 mM KCl, 2.5% glycerol and
0.1 mM EDTA to mimic those used in the pull down assay. The
arrows highlight the Sp1 and Sp3 protein complexes.
(TIF)
Figure S5 Expression of GDF5, Sp1, Sp3, P15 and DEAF-1 in
joint tissues. The expression levels of (A) GDF5, (B) Sp1, (C) Sp3,
(D) P15 and (E) DEAF-1 were detected using real time PCR. The
cartilage, synovium and fat pad tissue sample RNAs were
extracted from OA patients following joint replacement surgery.
NOF (neck of femur fracture) is RNA extracted from the cartilage
taken from hip samples of patients without OA. Error bars denote
the standard error of the mean (SEM). The data represents
combined numbers of 30 OA cartilage, 12 NOF cartilage, 10
synovium and 10 fat pad samples.
(TIF)
Figure S6 Validation of DEAF-1 siRNA treatment. Examina-
tion of the effect of DEAF-1 siRNA treatment on DEAF-1 EGFP
expression. Immunoblots demonstrating the effect of over
expressing DEAF-1 EGFP (D1 EGFP) and the effect of
concurrently depleting DEAF-1 expression using siRNA (DEAF-
1 EGFP D1 siRNA). Protein extracted from cells that are over
expressing DEAF-1 EGFP and that have been treated with the
NTsiRNA control (D1 EGFP NTsiRNA) were used for assessing
basal protein expression. b-Actin was used as a loading control.
Arrow indicates DEAF-1 EGFP expression.
(TIF)
Figure S7 Knockdown of candidates in SW1353 chondrosar-
coma cells and fold change in GDF5 expression. (A) Expression
levels of Sp1, Sp3, P15 and DEAF-1 mRNA are shown as a
percentage of the control non-targeting siRNA (NTsiRNA) treated
cells following Sp1, Sp3, P15 and DEAF-1 siRNA knockdown.
Error bars denote the standard error of the mean (SEM). *p,0.05,
***p,0.001, calculated relative to the NTsiRNA value using a
Students 2 tailed t-test. (B) Immunoblots demonstrating Sp1, Sp3,
P15 and DEAF-1 protein depletion following siRNA treatment.
Protein extracted from cells treated with the NTsiRNA control
were used for basal protein expression whilst b-Actin was used as a
loading control. (C) Fold change in GDF5 expression following
Sp1, Sp3, P15 and DEAF-1 siRNA knockdown and shown relative
to the NTsiRNA control. Error bars denote the SEM.
***p,0.001, calculated using a ANOVA.
(TIF)
Figure S8 Knockdown of candidates in human articular
chondrocytes. (A) Expression levels of Sp1, Sp3, P15 and DEAF-1
mRNA are shown as a percentage of the control non-targeting
siRNA (NTsiRNA) treated cells following Sp1, Sp3, P15 and
DEAF-1 siRNA knockdown. Error bars denote the standard error
of the mean (SEM). *p,0.05, ***p,0.001, calculated relative to
the NTsiRNA value using a Students 2 tailed t-test. (B)
Immunoblots demonstrating Sp1, Sp3 and P15 protein depletion
following siRNA treatment. Protein extracted from cells treated
with the NTsiRNA control were used for basal protein expression
whilst b-Actin was used as a loading control. (C) Fold change in
GDF5 expression following Sp1, Sp3, P15 and DEAF-1 siRNA
knockdown in human articular chondrocytes relative to the
NTsiRNA control. Error bars denote the SEM. *p,0.05,
calculated using a ANOVA.
(TIF)
Figure S9 Immunofluorescence following over expression.
Nuclei are stained blue with DAPI, shown in the first row. The
localisation of the EGFP fusion proteins (Empty EGFP, Sp1
EGFP, Sp3 EGFP, P15 EGFP and DEAF-1 EGFP) is shown in the
second row (EGFP). The final row shows the merged DAPI and
EGFP images (Merge).
(TIF)
Figure S10 Co-immunoprecipitation (CoIP) of Sp1, Sp3, P15
and DEAF-1. Immunoprecipitations for Sp1, Sp3 and P15 were
performed using SW1353 untransfected cell lysate, whilst DEAF-1
was immunoprecipitated with an EGFP antibody using SW1353
cell lysate over expressing DEAF-1 EGFP. Inputs represent 12.5%
volume of untransfected lysate and 11.5% of transfected lysate. (A)
Immunoblot examining the expression of Sp1. Immunoprecipita-
tion with Sp1 antibody was used as a positive control, whilst a
species matched IgG was used as a negative control. Sp3, P15 and
DEAF-1 were immunoprecipitated to detect co-precipitating Sp1.
The arrow highlights Sp1. (B) Immunoblot examining the
expression of Sp3. Immunoprecipitation with Sp3 antibody was
used as a positive control, whilst a species matched IgG was used as
a negative control. Sp1, P15 and DEAF-1 were immunoprecipitated
to detect co-precipitating Sp3. The arrows highlight Sp3. (C)
Immunoblot examining the expression of P15. Immunoprecipita-
tion with the P15 antibody was unsuccessful, thus could not be used
as a positive control, whilst a species matched IgG was used as a
negative control. Sp1, Sp3 and DEAF-1 were immunoprecipitated
to detect co-precipitating P15. The arrow highlights P15. (D)
Immunoblot examining the expression of DEAF-1. Immunopre-
cipitation of DEAF-1 using the EGFP antibody and the EGFP
transfected lysate is shown. Sp1, Sp3 and P15 were immunopre-
cipitated using the untransfected lysate to detect co-precipitating
endogenous DEAF-1. The arrow on the left highlights DEAF-1
EGFP and the arrow on the right highlights endogenous DEAF-1.
(TIF)
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Table S1 The sequences of the rs143383 probes and of the
competitor oligonucleotides used in the EMSA experiments. The
forward primer sequences are shown. The consensus binding motif
of the competitor proteins was identified using online prediction
tools and is underlined. The flanking sequences were randomly
generated.
(DOC)
Table S2 The C/T allelic ratios following over expression of the
trans-acting factors. The promoter activities of the C and T GDF5
luciferase vectors were compared to derive C/T ratios, which are
shown for the GDF5 vectors in addition to the empty EGFP vector
(C/T) and for when these vectors were co-transfected in
combination with Sp1 (C/T+Sp1), Sp3 (C/T+Sp3), P15 (C/
T+P15), DEAF-1 (C/T+D1), Sp1 and Sp3 (C/T+Sp1+Sp3), Sp1
and DEAF-1 (C/T+Sp1+DEAF-1), and Sp3 and DEAF-1 (C/
T+Sp3+DEAF-1). P-values were calculated using a Students 2
tailed t-test comparing the allelic ratios of each treatment group to
either C/T, C/T+Sp1 (+Sp1), C/T+Sp3 (+Sp3) or C/T+D1
(+D1).
(DOC)
Table S3 The primers used in our experiments. (A) Nucleotide
sequences of the primers and of the probes used for the real time
RT-PCR assays measuring gene expression. (B) Nucleotide
sequences of the primers used for creating the 212 bp fragment
used in the oligonucleotide pull down assay, of the primers used for
PCR following ChIP, and of the primers used to create the inserts
for cloning in the overexpression vectors (the restriction enzyme
sites used are underlined). F, Forward; R, Reverse.
(DOC)
Table S4 Details of the antibodies used in our experiments.
(DOC)
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